ORM PTO-144 REV.7-80)	1		S. DEPARTMENT TENT AND TRAD		ATTY. DOCKET NO. 210121.462C6		APPLICATION NO. 09/827,271		
SUPPL	.EME	NATE OR MAT STATEMEN'	ION DISCLO	SURE	APPLICANTS Marc W. Retter an	d Gary R	. Fanger		
(Use several sheets if necessary)					FILING DATE GROUP ART UNIT April 4, 2001 1631				
			U.S.	PATENT 1	DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLAS	S SUBCLASS	FILING IF APPRO	
	AA						REC	EIV	EC
	AB							1 4 21	
	AC					_	TECH CEN		
	AD AE						— JECH CEN	 EH 18	MAID
	AF								
	AG								
	AН								
	Al								
	AJ					<u> </u>			<u> </u>
	, — · ·		FORE	IGN PATEN	NT DOCUMENTS			TRANSI	LATION
		DOCUMENT NUMBER	DATE		COUNTRY			YES	NO
_/	AK	WO 01/57272	08/09/01	WIPO					
4/	AL	WO 01/16318	03/08/01	WIPO	<u></u>				
\mathbb{N}	AM	WO 02/02587	01/10/02	WIPO					
14	AN	WO 02/02624	01/10/02	WIPO					
71	AO	WO 02/10187	02/07/02	WIPO					
	AP	WO 02/16429	02/28/02	WIPO					
	AQ	WO 02/16581	02/28/02	WIPO					
		ОТН	R PRIOR A	RT (Including	Author, Title, Date, Pertiner	nt Pages, Etc.)	i		
· · · · · · · · · · · · · · · · · · ·	AR								
EXAMIŅ	AS				DATE CONSIDERI				

FORM PTO-14 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

APPLICATION NO. ATTY, DOCKET NO. 210121.462C6

09/827,271

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)					APPLICANTS		_			
				ENT	Marc W. Retter and Gary R. Fanger					
					FILING DATE	1	GROUP ART UNIT			
					April 4, 2001	1	631	1		
			U.S.	PATENT 1	DOCUMENTS			<u> </u>		
*EXAMINER INITIAL		DOCUMENT NUMBER DATE			NAME	CLASS SUBCLASS		FILING IF APPR	DATE OPRIATE	
	AA									
	1		FOREIG	GN PATE!	NT DOCUMENTS		· · · · · · · · · · · · · · · · · · ·			
. 1	T	DOCUMENT NUMBER	DATE	<u> </u>	COUNTRY			TRANS YES	LATION	
-11/	 			-		REC	EIVED	YES	NU	
	AB	WO 00/36107	06/22/00	WIPO		, , , , , ,				
5	AC					MAR	1 ½ 2003			
	AD					:ሶ ሀ ሶሮ እ	TER 1600/29	nn		
	1	OTHE	R PRIOR A	RT (Including	I L Author, Title, Date, Pertinent Pa	-	1L11 1000/23	VV		
	T				of the Beginning," Tu		logy 22: 345	-347, 2	2001.	
	AE	l llovig, E. c. a	1., 0/1 125	. The Bud	. 01 11.0 2 0 5 11.11.11.15, 1 2 11.			,		
Λ										
	AF	O'Brien, T.J.	et al., "The	CA 125 G	ene: A Newly Discove	red Exte	nsion of the	Glyco	sylated	
	Ar	N-Terminal Domain Doubles the Size of This Extracellular Superstructure," Tumor Biology								
		23: 154-169,	2002.							
	AG	O'Brien, T.J. et al., "The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences," <i>Tumor Biology 22</i> : 348-366, 2001.								
111	"									
11/	ļ									
11/1/	AH	Schummer, M	1. et al., "Co	omparative	hybridization of an ar	ray of 21	500 ovariar	cDN/	As for	
\\\\\		the discovery	of genes ov	erexpress	ed in ovarian carcinoma	as," Gen	e 238: 375-3	85, 19	99.	
	<u> </u>		-							
1	AI				acts with fasciculation				-1	
			nding protein (CIB) an			itally				
	_				ube," Eur. J. Biochem.				. 4"	
	AJ				g of the CA125 Ovarian					
		I I	a new mucin, MUC16," Journal of Biological Chemistry 276(29): 27371-27375, July 20,							
		2001.					1 10000			
	AK				antigen CA125 is enco	oded by	tne MUC16	mucin	gene,	
		International	Journal of	Cancer 98	2: 737-740, 2002.					
EXAMIN	ER/	5 /	11,	and the second s	DATE CONSIDERED)				
		Sinds W	1		5/17/204					
* EXAMI	VER:	Initial if reference consider conformance and not consi	ed, whether or no dered. Include o	ot criteria is in o opy of this form	conformance with MPEP 609. Dr n with next communication to app	aw line throi licant(s).	ugh citation if not	ın		

RM PTO-144	MIN Q	1 1 W.J	.S. DEPARTMENT (ATTY, DOCKET NO.		ICATION NO.		
EV.7-80)	70	TO THE STATE OF TH	TENT AND TRAD	MAKKOTTEL	210121.462C6 APPLICANTS	109/	827,271		
INF	ORMA	morbisclosu	RE STATEM	ENT	Marc W. Retter an	d Gary R. Fa	nger		
		(Use several sheets if ne	cessary)		FILING DATE April 4, 2001	GRO	UP ART UNIT		
			U.S.	PATENT I	DOCUMENTS				
XAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		DATE OPRIATE
	AA		CODE	ON DATE	UT DOCUMENTS			L	
	7-1	DOCUMENT	DATE	GN PATE	NT DOCUMENTS COUNTRY	CLASS	SUBCLASS	TRANS	LATION
		NUMBER		į				YES NO	
	AB							YES	110
		ОТН	ER PRIOR A	RT (Including	Author, Title, Date, Pertinen	it Pages, Etc.)	<u> </u>	L	L
11/	AC				of ovarian cancer:		tions," Sen	inars	in
		Oncology, 2.	5(3):381-396	5, 1998.				iinars GI4 ²	1700
/ 	AD	Gillespie et al., "Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue," British Journal of Cancer, 78(6):816-821, September, 1998.						8.	
	AE	Heller et al., microarrays,	"Discovery" Proc. Natl	and analys . Acad. Sci	is of inflammatory d . <i>USA 94</i> :2150-2155	lisease-relate i, March, 199	d genes usi 7.	ng cD	NA
	AF	complete sea		0 new cDN	oding sequence of us IA clones from brain				teins
	AG	Jin et al., "H	luman T cell protein MAI	leukemia	virus type 1 oncopro	tein tax targe	ets the hum	an mit	otic
		1 .			5.01-51, Apin 5, 155	-			
	АН	Köhler et al Antibody A	CA125 – Re	nerapy of C sults of the	Ovarian Carcinoma w Phase LB Study," (vith the Mone	oclonal An and Fraenh	ti-Idiot teilkun	type de,
	+	Köhler et al. Antibody A 58(4):180-1 Ma et al., "U humoral and	CA125 – Re 86, April 19 Jse of encap I cellular im	nerapy of C sults of the 98 + (Engli sulated sing	varian Carcinoma w	vith the Mono Gebrutshilfe i	<i>and Fraenh</i> of anti-idi	eilkun iotypic	de,
	АН	Köhler et al. Antibody A 58(4):180-1 Ma et al., "U humoral and 1378, Nove Parker et al.	CA125 – Re 86, April 19 Use of encap I cellular im mber, 1998. "Scheme fo	nerapy of C sults of the 98 + (Engli sulated sing mune response	Phase LB Study," (sh Abstract). gle chain antibodies onses," Journal of Ph	with the Mond Gebrutshilfe to for induction tharmaceutical inding peptid	and Fraenh of anti-idi al Sciences, les based o	otypic 87(11):137 pende
	AH	Köhler et al. Antibody A 58(4):180-1 Ma et al., "U humoral and 1378, Nove Parker et al.	CA125 – Re 86, April 19 Use of encap I cellular im mber, 1998. "Scheme fondividual pe	nerapy of C sults of the 98 + (Engli sulated sing mune response	Ovarian Carcinoma was Phase LB Study," (ash Abstract). Igle chain antibodies onses," Journal of Phase Phases, "The Journal of Phase Phains," The Journal of Phase Phains," The Journal of Phase Phains, "The Journal of Phase Phains," The Journal of Phase	with the Mono Gebrutshilfe to for induction tharmaceutical inding peptid	and Fraenh of anti-idi al Sciences, les based o	otypic 87(11):137 pende
XAMIN	AH AI AJ NER	Köhler et al. Antibody A. 58(4):180-1 Ma et al., "I. humoral and 1378, Nove Parker et al. binding of i. January 1, 1	CA125 – Re 86, April 19 Use of encap I cellular import, 1998. "Scheme for a continuous per 1994. March 1994.	nerapy of C sults of the 98 + (Engli sulated sing mune respo or ranking p ptide side-o	Phase LB Study," (sh Abstract). gle chain antibodies onses," Journal of Ph	with the Mond Gebrutshilfe valuetion for induction tharmaceutical inding peptidal of Immunolated	of anti-idi al Sciences, les based o	otypic 87(11 n indep:):137 pende

	61		1
FORM PTO-1449 (REV.7-80)	NUL	SCHE) l
INICO	DM A'THO	T& TRADER	/CI

U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. PATENT AND TRADEMARK OFFICE 210121.462C6

APPLICATION NO. 09/827,271

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)											
				ENT	APPLICANTS Marc W Retter and Gary R Fanger						
				E14 I	Marc W. Retter and Gary R. Fanger						
					filing date Group art unit April 4, 2001						
			U.S.	PATENT	DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		DATE OPRIATE		
	ВА			<u> </u>				<u> </u>			
	, 		FOREI	GN PATEN	T DOCUMENTS		1				
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION			
							 	YES	NO		
	BB						<u> </u>				
				_	Author, Title, Date, Pertine		201.11				
(4)	ВС	peptides," An	Peoples et al., "Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides," <i>Annals of Surgical Oncology</i> , 5(8):743-750, December, 1998.								
(M)	BD		Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci., 93</i> :10614-10619, October, 1996.								
3	BE										
	BF										
	ВG										
	вн										
	Bi										
	ВЈ										
EXAMINE	R	Bearder 14	AM		DATE CONSIDER ≤ 17	ED /azy					

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).